Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Glucose clamp Clear all

Conditions: Pharmacokinetics, Pharmacodynamics, Insulin Aspart
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Hypoglycemia
Interventions: Insulin, Glucose, Potassium phosphate; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes, Gastric Bypass
Interventions: Mixed Meal Tolerance test, Hyperglycemic clamp; Procedure
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 19 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sleep, Insulin Resistance, Type 2 Diabetes
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 40 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes, Hypoglycemia
Interventions: hyperinsulinemic-hypoglycemic clamp, 13C-MRS procedure/Acetate infusion; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hypoglycemia
Interventions: Glucose clamp; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Disproportionate Shape, Expanded Fat Pads
Interventions: Standard of Care with Liposuction, Standard of Care without Liposuction; Procedure · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Beta-hydroxybutyrate, Normal Saline; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes
Interventions: Glycemic clamping; Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 21 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Obesity, Insulin Resistance
Interventions: Fat biopsy during scheduled abdominal surgery, Fat Aspiration, Fish Oil Supplement; Procedure · Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 50 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Obesity, Impaired Glucose Tolerance, Type 2 Diabetes Mellitus
Interventions: Rosiglitazone, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 10 Years to 18 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Metabolism
Interventions: Overnight Metabolic Flexibility, Clamp Metabolic Flexibility; Procedure
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Insulin Resistance, Type 2 Diabetes, Obesity & Overweight, Healthy Adult Participants
Interventions: Alpelisib 300 mg, Alpelisib Challenge Test (ACT): Mixed Meal Tolerance Test (MMTT) after taking alpelisib, Hyperglycemic clamp; Drug · Diagnostic Test
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Very Long-chain Acyl-CoA Dehydrogenase Deficiency, Trifunctional Protein Deficiency, Long-chain 3-hydroxyacyl-CoA Dehydrogenase Deficiency, Medium-chain Acyl-CoA Dehydrogenase Deficiency, Normal Volunteers, Carnitine Palmitoyltransferase II Deficiency, Myopathic
Interventions: Intralipid/Heparin, Glycerol/Saline, Hyperinsulinemic euglycemic clamp; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Insulin Resistance, Hyperinsulinemia, Metabolic Dysfunction Associated Steatotic Liver Disease, Non-Alcoholic Fatty Liver Disease, Prediabetic State, Obesity
Interventions: Insulin human, Octreotide Acetate, Glucagon, Growth Hormone, Human, 20% D-glucose (aq), [6,6-2H2] D-glucose, [1-13C1] sodium acetate, Nestle BOOST Plus, KIND Bar, Harvard Apparatus PHD ULTRA CP syringe pump, Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer; Drug · Diagnostic Test · Dietary Supplement + 1 more
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions: Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo; Drug
Lead sponsor: Kalie Tommerdahl; Other
Eligibility: 12 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Obesity, Metabolic Syndrome
Interventions: Metabolic flexibility in the fasted state, Metabolic flexibility in euglycemic-hyperinsulinemic clamp, Metabolic flexibility in the metabolic chamber; Diagnostic Test · Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 20 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes, Obesity
Interventions: Pre-study dietary and exercise instruction., Screening examination and oral glucose tolerance test, Euglycemic clamp, VO2max., Acute exercise bout, Percutaneous needle muscle biopsies; Behavioral · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 59 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Type 2 Diabetes
Interventions: Maximal ATP Production (ATPmax), Exercise Testing (VO2max), Muscle Biopsy, Adipose Tissue Biopsy, Hyperinsulinemic euglycemic clamp, PET imaging; Other · Procedure
Lead sponsor: AdventHealth Translational Research Institute; Other
Eligibility: 30 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Bariatric Surgery
Interventions: GLP-1; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sleep, Sleep Deprivation, Insulin Resistance, Type 2 Diabetes
Interventions: 5-hour bedtime, 8.5-hour bedtimes; Other
Lead sponsor: University of Chicago; Other
Eligibility: 21 Years to 40 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes Mellitus, Non-Insulin Dependent, Non-Insulin Dependent
Interventions: Acetylcholine; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: Empagliflozin 25 MG, Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 30 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Malignant Neoplasm
Interventions: assessment of therapy complications, laboratory biomarker analysis; Procedure · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

Glucose Metabolism in the Immediate and Short Term Follow up After Bariatric Surgery

Glucose Metabolism and Sleep in People With Family History of Type 2 Diabetes.

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation

Differing Levels of Hypoglycemia

Mechanisms Defending Fat Mass in Humans After Lipectomy

Brain Ketone Metabolism in Type 1 Diabetes

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

Understanding the Relationship Between Inflammation and Insulin Resistance in the Adipose Tissue

Effects of Rosiglitazone on the Metabolic Phenotype of Impaired Glucose Tolerance in Youth

Validating a Novel Approach to Assess Metabolic Flexibility in a Respiratory Chamber

Alpelisib Challenge Test (ACT)

Fatty Acid Oxidation Defects and Insulin Sensitivity

Human Models of Selective Insulin Resistance: Pancreatic Clamp

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Impact of Metabolic Flexibility on Changes in Metabolic Health

PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes

Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes

The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition

Sleep Loss and Glucose Metabolism in People With Family History of Type 2 Diabetes.

Study of the Effects of Vitamin C on Patients With Type 2 Diabetes

SGLTi, Hepatic Glucose Production and Ketogenesis

Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant